The results of these analyses from the EMPA-KIDNEY, DAPA-CKD and other large trials suggest widespread use of SGLT2 inhibitors should substantially reduce the future global burden of kidney failure due to both diabetic and non-diabetic primary causes of kidney disease. Here, SLC5A2 is linked to kidney disorder.